Indication
Metastatic Melanoma
136 clinical trials
152 products
27 drugs
1 abstract
Product
ANV419Clinical trial
A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)Status: Recruiting, Estimated PCD: 2024-09-01
Product
IpilimumabProduct
PembrolizumabProduct
IO102-IO103Clinical trial
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
sotigalimabClinical trial
A Phase II Multicenter, Open-label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody Sotigalimab (APX005M) With or Without Stereotactic Body Radiation Therapy in Adults With Unresectable or Metastatic MelanomaStatus: Terminated, Estimated PCD: 2022-07-29
Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TemozolomideProduct
TILT-123Product
ST101Clinical trial
A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating LymphocytesStatus: Active (not recruiting), Estimated PCD: 2023-12-12
Product
ONC-392Clinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-06-30
Product
AtezolizumabProduct
IN10018Product
CobimetinibProduct
GebasaxturevClinical trial
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic MelanomaStatus: Terminated, Estimated PCD: 2023-07-12
Clinical trial
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic MelanomaStatus: Completed, Estimated PCD: 2020-11-16
Product
APX005MProduct
NivolumabProduct
LomvastomigClinical trial
An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Product
RO7247669Clinical trial
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-07-19
Product
CMP-001Product
Gebasaxturev ITuClinical trial
A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2028-03-01
Product
BDTX-4933Clinical trial
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive NeoplasmsStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)Status: Completed, Estimated PCD: 2017-09-12
Clinical trial
A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS MutationsStatus: Completed, Estimated PCD: 2014-01-07
Product
MEK162Clinical trial
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2029-08-09
Product
LN-145-S1Product
LifileucelProduct
LN-145Product
TLPLDCClinical trial
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic MelanomaStatus: Completed, Estimated PCD: 2024-02-05
Clinical trial
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.Status: Completed, Estimated PCD: 2019-10-30
Clinical trial
Overall Survival (OS) in Patients With Metastatic BRAFV600-mutant Melanoma Treated With Encorafenib Plus Binimetinib in the COLUMBUS Trial Versus in Real-world Practice DataStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Product
Enco+biniProduct
[203Pb]VMT01Product
[212Pb]VMT01Clinical trial
A Phase I/IIa, First-In-Human, Multi-Center Dose Escalation and Dose Expansion Study of [203/212Pb]VMT01 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Patients With Previously Treated Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-label, Phase I Study of NEO-PTC-01 in Patients With Advanced or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-10-31
Product
NEO-PTC-01Product
IL-2Product
αPD-1 therapyProduct
VemurafenibClinical trial
A Phase II Two Cohort Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesStatus: Completed, Estimated PCD: 2021-06-07
Clinical trial
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-30
Product
OBX-115Clinical trial
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)Status: Completed, Estimated PCD: 2021-04-15
Clinical trial
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-01-15
Clinical trial
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced CancerStatus: Completed, Estimated PCD: 2021-02-10
Product
EncorafenibProduct
TLPLDC VaccineProduct
RetifanlimabProduct
GemcitabineProduct
CetuximabClinical trial
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-06-01
Product
IOV-4001Clinical trial
A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma PatientsStatus: Terminated, Estimated PCD: 2018-04-05
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or TransplantStatus: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), In Combination With Pembrolizumab (Anti-PD-1), In Participants With Advanced Or Metastatic MelanomaStatus: Completed, Estimated PCD: 2022-07-14
Product
PV-10Product
RO6874281Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2019-10-24
Product
ADXS-NEOClinical trial
Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden: An Observational StudyStatus: Completed, Estimated PCD: 2021-12-03
Product
ST316Product
Dabrafenib+TrametinibProduct
Ipilimumab+NivolumabProduct
Vemurafenib+CobimetinibProduct
Encorafenib+BinimetinibProduct
Encorafenib + BinimetinibClinical trial
'An Open Label, Multicentre, Phase I Study to Evaluate the Impact of Moderate and Severe Hepatic Impairments on the Pharmacokinetics and Safety of Encorafenib in Combination With Binimetinib in Adult Patients With Unresectable or Metastatic BRAF V600-mutant Solid Tumors'.Status: Withdrawn, Estimated PCD: 2023-05-01
Product
LY3214996Product
Nab-paclitaxelProduct
MidazolamProduct
AbemaciclibProduct
AV-MEL-1Clinical trial
An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-07-11
Product
dextromethorphanProduct
caffeineProduct
midazolamProduct
BupropionProduct
binimetinibProduct
modafinilClinical trial
A Study to Evaluate the Safety and Efficacy of Intratumoral Injection of PV-001-DV in Combination With Infusion of PV-001-DC in Patients With Advanced MelanomaStatus: Not yet recruiting, Estimated PCD: 2024-08-30
Product
High Dose Interleukin-2Product
PV-001-DCClinical trial
Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-05-01
Product
losartanProduct
omeprazoleProduct
rosuvastatinProduct
encorafenibClinical trial
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic MelanomaStatus: Terminated, Estimated PCD: 2015-07-01
Product
BinimetinibClinical trial
A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Pivotal Bioequivalence Study Comparing Binimetinib 3 x 15 mg and 45 mg Tablets in Healthy ParticipantsStatus: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)Status: Terminated, Estimated PCD: 2021-06-01
Product
Tilsotolimod with IpilimumabClinical trial
A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingStatus: Not yet recruiting, Estimated PCD: 2025-11-29
Drug
AtezolizumabClinical trial
Phase I/II Study of Aerosol Interleukin-2 for Pulmonary MetastasesStatus: Active (not recruiting), Estimated PCD: 2026-04-30
Product
AldesleukinClinical trial
Pilot Study of Pembrolizumab and Stereotactic Radio-Surgery (SRS) for Patients With Melanoma or Non-Small Cell Lung Cancer (NSCLC) Brain Metastases (BM)Status: Completed, Estimated PCD: 2020-11-19
Clinical trial
Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsStatus: Not yet recruiting, Estimated PCD: 2028-09-30
Product
RelatilmabClinical trial
A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2028-05-01
Product
RigosertibClinical trial
Phase II Study of Ipilimumab Plus Temozolomide in Patients With Metastatic MelanomaStatus: Completed, Estimated PCD: 2016-08-01
Product
TMZClinical trial
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Drug
cyclophosphamideProduct
FludarabineProduct
Young TILClinical trial
Phase I/II Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
GSK2636771Clinical trial
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous MelanomaStatus: Active (not recruiting), Estimated PCD: 2027-01-20
Product
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1Clinical trial
A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-Beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Drug
fludarabineClinical trial
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-12-13
Product
ImatinibClinical trial
A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 ExperiencedStatus: Recruiting, Estimated PCD: 2027-01-31
Product
LenvatinibClinical trial
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic MelanomaStatus: Completed, Estimated PCD: 2022-03-04
Product
PlaceboProduct
VancomycinProduct
Matching PlaceboProduct
SER-401Clinical trial
A Phase 2 Study of Palliative Radiation and Combination Sequential Immunotherapy for Metastatic Cutaneous Melanoma and Ocular MelanomaStatus: Completed, Estimated PCD: 2021-05-04
Clinical trial
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous CancersStatus: Recruiting, Estimated PCD: 2027-01-31
Product
PrednisoneDrug
sirolimusClinical trial
Area B: Precise DCE-MRI Assessment of Brain TumorsStatus: Terminated, Estimated PCD: 2023-11-22
Product
BevacizumabClinical trial
A Proof of Concept Study of TBio-4101 (an Autologous Selected and Expanded Tumor Infiltrating Lymphocyte [TIL] Therapy) Using Short-Term Cultured, Selected Autologous TIL Following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients With Relapsed or Refractory Melanoma (Phase 1)Status: Recruiting, Estimated PCD: 2024-08-31
Drug
TBio-4101Clinical trial
A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesStatus: Completed, Estimated PCD: 2023-11-30
Drug
AbexinostatClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Clinical trial
Phase I and II Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain MetastasisStatus: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable DiseaseStatus: Recruiting, Estimated PCD: 2025-01-09
Product
Poly ICLCProduct
Recombinant Flt3 LigandDrug
IL-2Clinical trial
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)Status: Completed, Estimated PCD: 2019-11-20
Product
Neoantigen Peptide VaccineClinical trial
A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment With Nivolumab With Either Adjuvant Ipilimumab or Relatlimab in Adult Patients With Surgically Resectable Melanoma Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2027-01-01
Clinical trial
Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial MetastasesStatus: Completed, Estimated PCD: 2023-12-08
Product
Bintrafusp AlfaProduct
PimasertibClinical trial
Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain TumorsStatus: Completed, Estimated PCD: 2023-09-18
Product
18F-FMAUClinical trial
Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
DabrafenibProduct
E6201Clinical trial
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2013-02-15
Product
SargramostimClinical trial
Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the LungStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Product
Nivolumab + RelatlimabClinical trial
A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Drug
T-VECClinical trial
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/YearStatus: Recruiting, Estimated PCD: 2025-01-31
Product
MemantineClinical trial
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2017-04-05
Clinical trial
Phase 1 Study of the Administration of Ipilimumab Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE With Nivolumab Administered IV in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmStatus: Active (not recruiting), Estimated PCD: 2023-10-04
Product
Antiretroviral TherapyClinical trial
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-02-03
Product
AvapritinibClinical trial
Phase 1 Study of the Administration of STI-3031 (Anti-PDL1) Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE in Patients With In-Transit Melanoma (Sofusa-2)Status: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-09-01
Product
Interleukin-2Clinical trial
Surgery of Melanoma Metastases After Systemic Therapy - the SUMMIST TrialStatus: Withdrawn, Estimated PCD: 2023-09-03
Product
ImmunotherapyClinical trial
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal MelanomaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
TrametinibClinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV InfectionStatus: Active (not recruiting), Estimated PCD: 2025-11-02
Product
CabozantinibClinical trial
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With IpilimumabStatus: Completed, Estimated PCD: 2021-09-30
Clinical trial
Pilot Study to Test the Safety and Efficacy of the Combination of Imiquimod and Pembrolizumab for the Treatment of Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2021-10-01
Product
ImiquimodClinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesStatus: Completed, Estimated PCD: 2022-10-20
Product
Enzyme InhibitorDrug
mFOLFOX6Clinical trial
Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-03-06
Clinical trial
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
IbrutinibClinical trial
Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic MelanomaStatus: Terminated, Estimated PCD: 2018-10-18
Drug
interleukin-2Clinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive BiomarkerStatus: Terminated, Estimated PCD: 2019-03-22
Clinical trial
Phase II Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Product
AzacitidineClinical trial
Pilot Study of Exosomes Before and After BRAF Inhibitor Therapy in Patients With Advanced Unresectable or Metastatic BRAF Mutation-positive MelanomaStatus: Completed, Estimated PCD: 2015-12-01
Product
Blood testClinical trial
A Phase II Study of Open Label Low Dose Ipilimumab in Combination With Pembrolizumab in Metastatic Melanoma Patients With Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Phase II Study of Binimetinib With Encorafenib in Patients With Metastatic Melanoma and CNS MetastasesStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the BrainStatus: Active (not recruiting), Estimated PCD: 2022-10-10
Drug
encorafenibDrug
binimetinibClinical trial
Intralesional Influenza Vaccine for Patients With MelanomaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-11-27
Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SonidegibClinical trial
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant CancerStatus: Active (not recruiting), Estimated PCD: 2018-05-16
Product
UprosertibClinical trial
A Randomized Phase 2 Trial of Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2014-01-31
Product
LymphodepletionProduct
High Dose IL-2Clinical trial
A Blinded, Randomized Phase 2 Study of Troriluzole in Combination With Ipilimumab and Nivolumab in Patients With Melanoma Brain Metastases Previously Treated With Anti-PD-1 TherapyStatus: Terminated, Estimated PCD: 2023-05-29
Product
TroriluzoleDrug
VarlilumabClinical trial
A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK InhibitionStatus: Recruiting, Estimated PCD: 2026-12-31
Product
NilotinibClinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
UTD1Drug
AN0025Drug
doxorubicinDrug
fluorouracilProduct
IrinotecanClinical trial
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Patients by Transient Addition of BRAF and MEK Inhibitors Followed by Pembrolizumab: A Pivotal Open Label, Single-site StudyStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Drug
ipilimumabDrug
nivolumabProduct
OlaparibClinical trial
Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) Combination in Metastatic Melanoma Refractory to Prior Immune Checkpoint Inhibitor Therapy With and Without CNS DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
XmAb22841Product
XmAb23104Clinical trial
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesStatus: Recruiting, Estimated PCD: 2027-06-30
Drug
FOLFOXIRIClinical trial
Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell CarcinomaStatus: Withdrawn, Estimated PCD: 2027-07-01
Product
GR-MD-02Drug
LurbinectedinDrug
TiragolumabClinical trial
Effectiveness of Immunotherapy in the First-line Treatment of Disseminated Melanoma and Recognition of Prognostic and Predictive Biomarkers From the Primary Tumor, Stool and Body Fluids: PROTOCOL TRIALStatus: Recruiting, Estimated PCD: 2026-12-31
Product
Immune checkpoint inhibitorClinical trial
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2027-04-01
Drug
OBX-115Product
AcetazolamideProduct
FurosemideProduct
MesnaProduct
PemetrexedDrug
SelinexorClinical trial
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)Status: Active (not recruiting), Estimated PCD: 2023-06-13
Clinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersStatus: Active (not recruiting), Estimated PCD: 2022-10-11
Clinical trial
A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy With Tumour Infiltrating Lymphocytes (TIL) and Assessment of High Versus Low Dose Interleukin-2Status: Terminated, Estimated PCD: 2015-07-24
Product
TopotecanDrug
R-CHOPClinical trial
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and ResistanceStatus: Active (not recruiting), Estimated PCD: 2018-02-10
Clinical trial
Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Melanoma and Lung Cancer Patients With Leptomeningeal Disease (LMD)Status: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With T -Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic MelanomaStatus: Completed, Estimated PCD: 2023-04-21
Clinical trial
Copy of A Phase II Trial of Pembrolizumab (Anti PD-1) Therapy Combined With Sargramostim (GM-CSF) in Unresectable or Metastatic MelanomaStatus: Withdrawn, Estimated PCD: 2024-06-10
Clinical trial
Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose IL-2 in Patients With Metastatic MelanomaStatus: Completed, Estimated PCD: 2022-10-12
Clinical trial
Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2028-02-01
Product
GB1211Clinical trial
UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Completed, Estimated PCD: 2020-09-23
Product
TremelimumabProduct
MEDI3617Clinical trial
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
NavitoclaxClinical trial
Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2019-06-06
Product
CediranibProduct
SelumetinibClinical trial
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With MelanomaStatus: Recruiting, Estimated PCD: 2025-01-31
Drug
CDX-301Product
NEOVAXClinical trial
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA)Status: Active (not recruiting), Estimated PCD: 2024-12-08
Drug
TocilizumabClinical trial
A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse EventsStatus: Recruiting, Estimated PCD: 2025-06-30
Product
InfliximabProduct
RelatlimabClinical trial
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF MutationStatus: Completed, Estimated PCD: 2024-05-31
Product
LGX818Clinical trial
Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)Status: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
Phase II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic MelanomaStatus: Completed, Estimated PCD: 2024-04-12
Clinical trial
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2024-12-04
Product
TazemetostatClinical trial
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Ziv-AfliberceptClinical trial
A Phase Ib, Open, Mono-center, Dose-reduction Tolerability Study of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Product
AK104+AxitinibProduct
AK112+AxitinibProduct
IDO/PD-L1 peptide vaccineClinical trial
A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2022-09-23
Product
Bemcentinib